The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2019
Filed:
Apr. 02, 2015
Applicant:
Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);
Inventors:
Rajinder Singh, Belmont, CA (US);
Somasekhar Bhamidipati, Foster City, CA (US);
Pingyu Ding, Foster City, CA (US);
Donald Payan, Hillsborough, CA (US);
Marina Gelman, San Francisco, CA (US);
Todd Kinsella, Redwood City, CA (US);
Assignee:
Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); C07D 405/14 (2006.01); C07F 7/08 (2006.01); C07K 16/28 (2006.01); A61K 31/444 (2006.01); A61K 31/517 (2006.01); A61K 31/695 (2006.01); A61K 31/5377 (2006.01); A61K 31/635 (2006.01); A61K 39/395 (2006.01); C07D 401/14 (2006.01); C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 417/14 (2006.01); C07D 417/04 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/635 (2013.01); A61K 31/695 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07F 7/0812 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01);
Abstract
The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.